Kalaris Therapeutics appoints Leone Patterson to Board as Audit Committee Chair

Kalaris Therapeutics, Inc.

Leone Patterson elected Class III director effective April 3, 2025; term expires at 2026 annual meeting.
Patterson named Chair of Audit Committee; committee now includes Patterson, Adamis, and Jovan-Embiricos.
No arrangements or family relationships with other directors; standard indemnification agreement to be entered.
Company expects to adopt new non-employee director compensation program; Patterson will receive compensation once adopted.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Leone Patterson

Director and Chair of Audit Committee

KLRS · Kalaris Therapeutics, Inc.

Effective: 2025-04-03
Filed: April 4, 2025, 7:59 PM ET

On April 3, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”), the Board elected Leone Patterson to serve as a member of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Leone Patterson was elected as Director and Chair of Audit Committee at Kalaris Therapeutics, Inc..

Action: elected
Role: Director and Chair of Audit Committee

Exact text from the filing

On April 3, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”), the Board elected Leone Patterson to serve as a member of the Board, effective immediately.

View on SEC.gov

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-072869

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.